“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
On today's podcast, speaker and rare disease advocate David Rose talks with Biorasi's Dr. Raul Silveira about occipital horn syndrome and supporting rare disease...
"It's amazing how many companies there are and how many opportunities for a kind of a match between a human that needs some help...
"I learned very early on that the stupidest cancer cell was cleverer than the cleverest oncologist." - Justin Stebbing, Editor-in-Chief of Oncogene, previously the...